On 18 September 2024, NMIN spin-off company NanoVation Therapeutics (NTx) announced its entry into a multi-target partnership with Denmark-based global healthcare company Novo Nordisk. The multi-year partnership aims to advance the development of novel genetic medicines targeting cardiometabolic and rare diseases. The approach will combine NTx’ proprietary long-circulating lipid nanoparticle… Read More »NMIN spin-off NanoVation Therapeutics partners with Novo Nordisk

On 6 May 2024, the Government of Canada announced Stage 2 of its integrated Canada Biomedical Research Fund (CBRF) and Biosciences Research Infrastructure Fund (BRIF) investments in the amount of $574 million for 19 projects at 14 research institutions across Canada. These investments, channelled through five national research hubs—located at… Read More »Funding released to national biomanufacturing hubs involving NMIN researchers & infrastructure

In July 2023, NMIN researcher Dr. Gang Zheng co-founded the new biotechnology company Nanogenix, NMIN’s seventh spin-off company. The company’s novel photo-immune therapy platform, based on the porphysome technology discovered by Dr. Zheng and developed in his lab, aims to change treatment prospects for cancer patients, with an initial focus… Read More »Dr. Gang Zheng co-founds NMIN’s 7th spin-off company